Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets

Mostrar otras versiones (1)

Containment of the COVID-19 pandemic requires reducing viral transmission. SARS-CoV-2 infection is initiated by membrane fusion between the viral and host cell membranes, mediated by the viral spike protein. We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Rory D., Schmitz, Katharina S., Bovier, Francesca T., Noack, Danny, Haagmans, Bart L., Biswas, Sudipta, Rockx, Barry, Gellman, Samuel H., Alabi, Christopher A., de Swart, Rik L., Moscona, Anne, Porotto, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654853/
https://www.ncbi.nlm.nih.gov/pubmed/33173865
http://dx.doi.org/10.1101/2020.11.04.361154
Descripción
Sumario:Containment of the COVID-19 pandemic requires reducing viral transmission. SARS-CoV-2 infection is initiated by membrane fusion between the viral and host cell membranes, mediated by the viral spike protein. We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets. Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co-housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals. These lipopeptides are highly stable and non-toxic and thus readily translate into a safe and effective intranasal prophylactic approach to reduce transmission of SARS-CoV-2.

Ejemplares similares